Holen Sie sich die Stockscreener-App
21.96
6.33%
-1.34
Schlusskurs vom Vortag:
$23.30
Offen:
$23.3
24-Stunden-Volumen:
1.31M
Relative Volume:
1.92
Marktkapitalisierung:
$2.85B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.93%
1M Leistung:
+12.67%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.90
$23.82
1-Wochen-Bereich:
$19.90
$23.82
52-Wochen-Spanne:
$18.50
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Firmenname
Kailera Therapeutics Inc
Sektor
Branche
Telefon
508-440-9475
Adresse
180 THIRD AVENUE, WALTHAM
Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
21.96 | 3.02B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-12 | Eingeleitet | Evercore ISI | Outperform |
| 2026-05-12 | Eingeleitet | JP Morgan | Overweight |
| 2026-05-12 | Eingeleitet | Jefferies | Buy |
| 2026-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-05-12 | Eingeleitet | TD Cowen | Buy |
| 2026-05-12 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Kailera reports 11.1% weight loss data - grafa.com
Kailera's obesity drug meets main goal of late-stage trials in China - Reuters
Kailera Therapeutics Announces Positive Topline Data From Two Hengrui Pharma Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 - marketscreener.com
Kailera’s weight-loss drug meets main goal of late-stage trials in China - hi99.com
Kailera's weight-loss drug meets main goal of late-stage trials in China - marketscreener.com
Kailera’s GLP-1 drug meets main goal of late-stage trials - WTVB
Kailera's GLP-1 drug meets main goal of late-stage trials - Yahoo Finance
Kailera Therapeutics Announces Positive Topline Data from - GlobeNewswire
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - Yahoo Finance
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
Kailera appoints Kathleen Tregoning as chief corporate affairs officer - The Pharma Letter
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Value Benchmark - marketscreener.com
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - The Manila Times
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Press Release: Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer - Moomoo
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to Russell 3000E Value Benchmark - marketscreener.com
Kailera Therapeutics, Inc. (KLRA) Total Assets (Quarterly) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Gross Margin (TTM) - Zacks Investment Research
Kailera Therapeutics, Inc. (KLRA) Net Income (TTM) - Zacks Investment Research
Enterprise value to revenue forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Return On Assets (TTM) - Zacks Investment Research
Price to sales forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc. (KLRA) Price Book Value - Zacks Investment Research
Price to book forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat
Price to earnings forward of Kailera Therapeutics, Inc. – NASDAQ:KLRA - TradingView
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P TMI Index - marketscreener.com
Latest KLRA ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
KLRA Technical Analysis & ETF Price Forecast - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Kardigan surges in Nasdaq debut after upsized $400 million IPO - marketscreener.com
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Kailera Therapeutics, Inc. Common Stock (NASDAQ: KLRA) Stock Price, News & Analysis - Kalkine
This Stock Is Up 58% This Year. Is It too Late to Buy? - AOL.com
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic? - Yahoo! Finance Canada
Parabilis sets biotech IPO record with $670M raise - MSN
Parabilis Is Now the Largest VC-Backed Biotech IPO - Morningstar
Kailera (KLRA) CEO exercises stock options, now holds 38,094 shares - Stock Titan
Parabilis now the largest VC-backed biotech IPO - Yahoo Finance
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record - Citeline News & Insights
Parabilis sets a record with a $670M biotech IPO - BioPharma Dive
Parabilis takes top spot, pricing largest biopharma IPO at $670M - BioWorld News
Parabilis Medicines raises $670M in upsized IPO - Axios
Parabilis targets $745 million in record-setting biotech IPO - The Pharma Letter
Cancer biotech Parabilis books record IPO, raising $670m - pharmaphorum
Parabilis ups planned IPO haul to record-setting $637M - Fierce Biotech
3 potential takeover targets in obesity - Pharma Voice
Finanzdaten der Kailera Therapeutics Inc-Aktie (KLRA)
Es liegen keine Finanzdaten für Kailera Therapeutics Inc (KLRA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kailera Therapeutics Inc-Aktie (KLRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
500,000 |
8,000,000 |
10,776,820 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
| Koppel Adam | Director |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Bain Capital Life Sciences Inv | 10% Owner |
Apr 20 '26 |
Buy |
16.00 |
1,562,500 |
25,000,000 |
22,583,268 |
| Kaplan Andrew T. | Director |
Apr 20 '26 |
Buy |
16.00 |
8,398,438 |
134,375,008 |
26,255,581 |
1.21%
3.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):